Universal lipid screening at ages 9 to 11, recommended by the NHLBI panel, meets an insufficient-evidence USPSTF statement in this NU568 Unit 4 comparison of two guidelines for one composite child. Searches like "nu 568 unit 4 assignment example", "nu568 unit 4 sample" and "nu568 unit 4 example" land here.
Screen His Cholesterol at 10 or Not? The NHLBI Expert Panel and the USPSTF Side by Side for One Boy's Well Visit
[Student Name]
Purdue University Global
NU568: FNP I - Primary Care Across the Lifespan
Unit 4 Guideline Comparison
[Instructor Name]
[Date]
The child is a composite; values and the family's decision are bracketed.
The Patient
[Noah], 10, is seen for a well visit. He is healthy, active in soccer and takes no medicines. BMI is at the 78th percentile, in the healthy range. Blood pressure is normal for age and height. His parents know of no early heart disease or high cholesterol in the family, but his father was adopted and knows little of his biological family's history. No one in the family has had their cholesterol checked recently.
Two Recommendations
1. NHLBI Expert Panel, 2011. Issuing body: the Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, assembled under the NHLBI and endorsed by the American Academy of Pediatrics. Population: all children and adolescents. Recommendation: universal lipid screening once between ages 9 and 11 and again between 17 and 21, with a nonfasting non-HDL cholesterol acceptable; targeted screening earlier for children with a family history or risk factors. Strength: graded on the panel's evidence scale, with the universal screening recommendation resting largely on expert consensus about detection. Evidence: observational data linking childhood lipids to adult atherosclerosis and the recognition that family history misses many children with familial hypercholesterolemia (Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, 2011).
2. USPSTF, 2023. Issuing body: the US Preventive Services Task Force. Population: asymptomatic children and adolescents aged 20 years or younger without a known diagnosis of lipid disorders. Recommendation: an I statement, meaning the Task Force could not tell from current evidence whether screening does more good than harm. Evidence: a systematic review that found no trials showing that childhood screening improves cardiovascular outcomes in adulthood, and limited data on the long-term harms and benefits of treatment started in childhood (US Preventive Services Task Force, 2023).
The editions matter. The USPSTF statement of 2023 reaffirms its 2016 conclusion, and the 2011 NHLBI guidance remains the version pediatric practices cite.
Why Two Careful Bodies Disagree
The two bodies asked different questions: the NHLBI panel asked whether screening would find children who need attention, and the USPSTF asked whether screening has been shown to improve the health those children will have as adults.
The NHLBI panel's question was about detection. Heterozygous familial hypercholesterolemia, a genetic condition that raises LDL cholesterol from birth and causes early heart disease, affects about 1 in 300 people (Akioyamen et al., 2017). Most children with it are not identified by family history, because the history is unknown, incomplete or not yet expressed in young parents. Universal screening at 9 to 11 finds many of them before puberty temporarily lowers cholesterol levels, and treatment with statins in childhood lowers LDL and appears safe over the medium term. Finding a child also leads to testing of parents and siblings, a process called cascade screening.
The USPSTF's question was about proven benefit. Its standard requires evidence that screening leads to better outcomes, not only that it finds abnormalities. No trial has followed screened children into adulthood to show fewer heart attacks or deaths, and such a trial would take decades. The Task Force also weighed potential harms: labeling, anxiety, and the costs and uncertain long-term effects of treatment in children with milder, non-genetic lipid elevations, who are the majority of those identified. With benefit unproven and harms uncertain, it concluded the evidence was insufficient, which is not the same as recommending against screening.
The disagreement therefore reflects different standards of evidence applied to overlapping data, not a factual dispute. Both documents agree that familial hypercholesterolemia matters and that children with a known family history or risk factors should be screened.
Applying Both to [Noah]
Under the NHLBI guidance, [Noah] is in the recommended age band for universal screening, and his father's unknown family history strengthens the case, since an absent history cannot reassure. Under the USPSTF statement, there is insufficient evidence to recommend for or against screening him; the Task Force leaves the decision to clinical judgment and patient preference.
In practice, many pediatric practices follow the NHLBI guidance because Bright Futures, the AAP's schedule of preventive care, includes a lipid screen between 9 and 11 years in its periodicity schedule (American Academy of Pediatrics, 2024).
The decision was explained to his parents in plain terms: a simple, nonfasting blood test could find an inherited cholesterol problem that affects about 1 in 300 children and is often missed without testing; if the result is high, it would be repeated and discussed; most children tested have normal results; and there is no proof yet that testing all children prevents heart disease decades later. His parents asked whether the result would change anything now. The answer was that for most children it would not, but for a child with the inherited form, it would lead to diet changes, possible medicine in the teen years and testing of the family.
Decision: [the parents chose screening; a nonfasting non-HDL cholesterol was drawn today]. The decision is recorded as theirs, made with the clinician, with both recommendations noted.
What a Clinician Owes the Family Under an I Statement
An I statement is sometimes read as permission to skip a topic. It is better read as an instruction to explain the uncertainty. When evidence is insufficient, the Task Force asks clinicians to consider the potential benefits and harms for the individual patient and the family's values. For [Noah]'s family, that meant three things: stating that expert groups disagree and why, describing the likely result and what would follow from each possibility, and leaving room to decline without being made to feel negligent. A family that declines screening at 10 can be offered it again at 17 to 21, the second window in the NHLBI guidance, when the young man can decide for himself.
The comparison also shows a limit of both documents. Neither addresses the child whose family history is unknown rather than negative. That gap affects many children, those adopted, those in foster care and those whose parents are young or estranged from their own families. For them, the NHLBI rationale is stronger, because the premise of targeted screening, a known history, does not hold.
What Would Change the Decision
A known family history of early heart disease or high cholesterol, obesity, diabetes, hypertension or smoking in the child would move him from universal into targeted screening, where both documents agree screening is reasonable. A non-HDL cholesterol of [145] mg/dL or higher would prompt a repeat fasting lipid panel and, if confirmed high, evaluation for familial hypercholesterolemia and testing of his parents.
References
Akioyamen, L. E., Genest, J., Shan, S. D., Reel, R. L., Albaum, J. M., Chu, A., & Tu, J. V. (2017). Estimating the prevalence of heterozygous familial hypercholesterolaemia: A systematic review and meta-analysis. BMJ Open, 7(9), e016461. https://doi.org/10.1136/bmjopen-2017-016461
American Academy of Pediatrics. (2024). Recommendations for preventive pediatric health care: Bright Futures/American Academy of Pediatrics periodicity schedule. https://downloads.aap.org/AAP/PDF/periodicity_schedule.pdf
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. (2011). Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary report. Pediatrics, 128(Suppl. 5), S213-S256. https://doi.org/10.1542/peds.2009-2107C
US Preventive Services Task Force. (2023). Screening for lipid disorders in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA, 330(3), 253-260. https://doi.org/10.1001/jama.2023.11330
How this NU568 Unit 4 example is structured
The comparison runs in three movements: describe each recommendation exactly, explain the disagreement, then apply both to the patient. Description is kept neutral and precise, quoting each document's population so that neither is stretched beyond it. The explanation section is the heart of the paper and the part most rubrics weight heavily; it identifies the different questions each body asked, one about detection and one about proven benefit, and the different standards of evidence each applied. Edition matters here, and the paper says so: the USPSTF statement is the 2023 reaffirmation of a 2016 conclusion, and the 2011 NHLBI guidance remains the version pediatric practices cite. Application closes the paper, noting that Bright Futures carries the screening in its periodicity schedule, which is why many practices follow it, and recording the decision as the family's, made with the clinician.
Get an NU568 Unit 4 example written to your instructions
Guideline comparisons in NU568 cover many pairs, from lipid and blood pressure screening to depression and developmental checks. Name the two documents the Unit 4 prompt pairs, then add the patient and the rubric. Compared by edition and population before both are applied, the sample returns in 24-48h, and the first one is free. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU568 Unit 4 questions, answered
What if my two guidelines actually agree?
Then the comparison explains the agreement and looks for differences in detail: age thresholds, intervals, the strength assigned or the evidence cited. Two documents rarely match in every element. If the prompt assumes disagreement where none exists, stating that plainly and showing the finer differences is more credible than inventing a conflict to fill the paper.
Should a USPSTF grade be compared directly with a professional society's strength of recommendation?
With care. The two systems use different scales and definitions, so a table can list each in its own terms, with a sentence explaining what each grade means. Converting one into the other invites error. Graders tend to credit a paper that keeps the systems distinct and explains how each body weighs the evidence behind its conclusion.
How do I know whether a guideline has been updated?
Go to the issuing body's own site rather than a summary page, since summaries lag behind. USPSTF statements show their status and date, and professional societies list current guidelines and any reaffirmations. Record the date you checked. Comparing an edition that has since been replaced is a costly mistake, however careful the analysis around it.